Context Therapeutics Inc. (CNTX) is a developer of small molecule and immunotherapeutics for the transformation of the care for breast and gynecological oncological issues. The lead pipeline candidate of the company in Phase 1b/2 clinical trials is ONA-XR for treating breast, endometrial and ovarian cancers.
CNTX stock price in the regular trading on March 11, 2022, with a decrease of 6.67% was $1.82. Its price rebounded by 7.14% at the last check of the aftermarket session.
CNTX: Events and Happenings
On March 08, 2022, CNTX reported that five abstracts had been nominated for the Annual Meeting of the American Association for Cancer Research 2022 poster presentations being held on April 8-13, 2022. On February 22, 2022, CNTX announced its Executive management’s participation at the Virtual Sachs 15th Annual European Life Sciences CEO Forum held on March 1-2, 2022.
On January 04, 2022, CNTX updated its Executive management’s presentation at the following investor conferences virtually.
- Biotech Showcase 2022 held January 10-12, and
- Edison Group Open House: Global Healthcare 2022 held January 25-27, 2022.
On December 09, 2021, CNTX informed about the positive clinical data of ONA-XR extended-release in postmenopausal patients with PR+ confirmed it enhanced suppression of tumor cell proliferation. The clinical results were presented at the 2021 San Antonio Breast Cancer Symposium.
CNTX: Key Financials
On December 2, 2021, CNTX released its third-quarterly financials for the three months ended September 30, 2021. Some important characteristics are discussed below.
Revenue
No revenues were recorded in the third quarter of 2021 as well as in the corresponding period of 2020.
EPS
Net loss basic and diluted per common share in Q3 2021 was $1.4 million or $4.0 corresponding to $0.9 million or $2.52 for the same period of 2020. Its EPS declined YoY.
Conclusion
During the peak pandemic period, CNTX stock down-performed by 64% as the global stock markets were facing recession. The company’s stock position is somehow better now with the improvement of the conditions. Currently, Friday’s aftermarket stock gain is attributed to uncertainty as no SEC filing or official press release is announced from the company neither an event is on the schedule immediately. The company has not yet reported the date for the fourth quarter of the 2021 financials release, but the estimations showed its EPS to be -$0.21.
